TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Paravalvular leak after TAVR continues to be a problem—but advances in technology are helping

Additional studies are still necessary, but researchers are hopeful that modern TAVR solutions will help limit paravalvular leak in the years ahead. 

COVID lockdown reopening

Number of TAVR sites has nearly tripled in recent years—but quality issues remain

While the improved access is clearly beneficial, researchers did uncover potential issues that will need to be addressed. 

New self-expanding TAVR system gains FDA approval

A full launch of the new system is scheduled for early 2022. 

Thumbnail

Repeat TAVR leads to better short-term outcomes than TAVR explantation

Repeat TAVR is expected to grow more and more common as time goes on, making it especially important to study its impact on patient outcomes.

Thumbnail

CAC scores help predict TAVR mortality

The analysis, published in Radiology, included more than 300 patients who presented with severe aortic stenosis.

‘Making good, better’: Next-gen TAVR techniques and protocols optimize patient care, boost efficiency

Sponsored by Medtronic

Innovation in the transcatheter aortic valve replacement (TAVR) space has upped the ante once again.

Thumbnail

AI model evaluates ECG data as well as cardiologists

The team's convolutional neural network was trained on data that is readily available at most facilities. 

TAVR outcomes similar after 1 year in low-risk bicuspid, tricuspid aortic stenosis patients

Lead author John Forrest, MD, a cardiologist at Yale School of Medicine, presented the findings at TVT 2021. He noted that it felt great to finally return to in-person conferences after COVID kept people at home for so long. 

Displaying 329 - 336 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup